For surgeons threading a catheter through the body's vascular highways, navigation is a high-stakes art form. It relies heavily on intermittent X-ray snapshots and the operator's tactile ‘feel’ for the instrument's position, a skill honed over years. The clinical outcome of a procedure to clear a clot or repair an aneurysm can hinge on this delicate, sometimes imprecise, feedback loop. Mosaic Intelligence Labs, a San Francisco startup that emerged from stealth in November, is betting $47 million that sensing, spatial intelligence, and robotics can make that process more precise and less dependent on individual experience [Business Wire, November 2026].
The Wedge: Sensing Beyond the Screen
Mosaic's initial focus is on minimally invasive endovascular surgery, where surgeons access treatment sites through the body's own network of blood vessels. The company's stated goal is to develop ‘intelligent surgical machines’ that provide continuous, real-time understanding of anatomy and instrument position [Business Wire, November 2026]. Its apparent wedge is a sensing-enabled catheter and robotic control system designed to help physicians navigate with less reliance on fluoroscopic X-ray guidance and operator feel [Runtime Wire, November 2026].
This approach targets a known technical challenge. Academic research notes that real-time tracking of guidewires and catheters is essential for advanced robotic control and operator awareness, but traditional sensor-embedded methods can introduce fabrication complexity and limit device miniaturization [arxiv.org, 2025]. Mosaic's bet is that its integrated system can overcome these hurdles, providing a clearer, data-rich picture of the surgical field from inside the vessel itself.
A Simulation-First Approach to Clinical AI
A notable part of Mosaic's technical strategy involves heavy use of synthetic data. Co-founder and CEO Dr. Ileana Pirozzi has said the company works with NVIDIA simulation software, and that models trained on this synthetic data performed better than those trained solely on real medical data [Binance, November 2026]. This simulation-first approach could accelerate development cycles and help address the scarcity of labeled, high-quality clinical datasets, a common bottleneck in medical AI.
The company is also building early clinical partnerships. Arizona-based health system HonorHealth is identified as a collaborator, though the nature of the partnership,whether it involves paid deployments, clinical trials, or research,is not detailed in public reports [Binance, November 2026]. For a device that will eventually require FDA clearance, such clinical collaborations are a critical step for gathering real-world feedback and validating the system's utility.
The Founders and the Funding
Mosaic was co-founded by two Stanford-trained scientists, Dr. Ileana Pirozzi and Dr. Alison “Ali” Kight Mackanic, who met during their doctoral studies [Business Wire, November 2026]. Pirozzi serves as CEO, while Mackanic is the CTO [The Next Web, November 2026]. The company's $47 million seed funding, announced upon its emergence from stealth, was raised across two rounds led by deep-tech investors 8VC and Fundomo, with participation from Lingotto Innovation and Obvious Ventures [Business Wire, November 2026] [The Next Web, November 2026].
The substantial seed round, uncommon in the capital-intensive surgical robotics sector, suggests investor confidence in the technical team and the specificity of the vascular focus. The funding is likely earmarked for the complex hardware and software development required, as evidenced by active hiring for roles like Hardware Lead and a ‘Founding Clinically Deployed Engineer’ [Ashbyhq, November 2026].
| Role | Name | Background |
|---|---|---|
| Co-Founder & CEO | Dr. Ileana Pirozzi | Stanford-trained scientist [Business Wire, November 2026] |
| Co-Founder & CTO | Dr. Alison “Ali” Kight Mackanic | Stanford-trained scientist [The Next Web, November 2026] |
Navigating a Crowded and Regulated Field
The ambition to augment endovascular surgery with robotics and AI is not uncharted territory. Established players like Johnson & Johnson (with its Auris Health acquisition) and Siemens Healthineers have significant portfolios, while a cohort of venture-backed startups continues to push innovation in robotic-assisted interventions. Mosaic's differentiation appears to rest on the integrated sensing layer and its focus on continuous spatial awareness within the vessel, rather than just robotic manipulation.
The path to market, however, is paved with regulatory milestones. The company's system will be subject to FDA Class II or likely Class III regulatory pathways, requiring substantial clinical evidence to demonstrate safety and efficacy. The risks here are multifaceted.
- Technical integration. Fusing reliable micro-sensors, robust AI-driven 3D reconstruction, and precise robotic controls into a single, sterilizable system that meets clinical-grade reliability is a profound engineering challenge.
- Clinical workflow adoption. Any new system must seamlessly integrate into the high-pressure environment of an operating room without disrupting surgical rhythm or adding complexity.
- Evidence generation. Building the clinical dataset required for regulatory submission and commercial credibility will be a multi-year, capital-intensive effort, even with a simulation-aided approach.
The company's most plausible answer to these challenges is its focused starting point. By concentrating on the vascular system and the specific problem of intra-procedural navigation, Mosaic can aim to build a best-in-class tool for a defined set of procedures before expanding its scope.
The Patient and the Procedure
The ultimate test for Mosaic's technology will be in procedures like thrombectomies for stroke or endovascular aneurysm repairs. For patients facing these conditions, the current standard of care involves the surgeon using fluoroscopy,a continuous X-ray video,to visualize contrast dye injected into the vessels, creating a shadowy roadmap. Navigation relies on interpreting these 2D images and feeling resistance through the catheter. It's a skilled but indirect method, with inherent limitations in visualizing soft plaque or the vessel wall itself, and it exposes both patient and clinical team to radiation.
Mosaic's proposition is a future where the surgical field is mapped in three dimensions from within, providing constant feedback and potentially reducing radiation dose. The next twelve months will be critical for the startup as it uses its seed capital to advance its prototypes, deepen its clinical partnership with HonorHealth, and navigate the early stages of the regulatory strategy that will determine if its intelligent machines can reach the operating room.
Sources
- [Business Wire, November 2026] Mosaic Emerges from Stealth with $47 Million to Build Intelligent Surgical Machines | https://www.businesswire.com/news/home/20261110289756/en/Mosaic-Emerges-from-Stealth-with-$47-Million-to-Build-Intelligent-Surgical-Machines---Treating-the-Body-from-Inside
- [The Next Web, November 2026] Mosaic Intelligence Labs raises $47m for AI surgical catheters | https://thenextweb.com/news/mosaic-intelligence-labs-47m-seed-ai-surgical-catheter
- [Runtime Wire, November 2026] Mosaic Intelligence Labs emerges from stealth with $47M to build sensing surgical robots | https://runtimewire.com/article/mosaic-intelligence-labs-47m-seed-surgical-robots
- [Binance, November 2026] AI Trends: Mosaic raises 47 million in seed funding to develop surgical robotics | https://www.binance.com/en/square/post/11-11-2026-ai-trends-mosaic-raises-47-million-in-seed-funding-to-develop-surgical-robotics-387063225083931
- [arxiv.org, 2025] Research on sensor-embedded tracking for endovascular robotics |
- [Ashbyhq, November 2026] Mosaic Intelligence Labs Job Listings | https://jobs.ashbyhq.com/mosaicintelligence